Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06926842 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)
A Phase 2 study of Obesity and Type 2 Diabetes, sponsored by Zealand Pharma.
- Active
- Registry status
- Phase 2
- Development phase
- 221
- Enrollment target
- 20
- Study locations
NCT06926842: Active Phase 2 study of Obesity and Type 2 Diabetes, sponsored by Zealand Pharma.
NCT06926842 is a Phase 2 study of Obesity and Type 2 Diabetes that is active but no longer recruiting, run by Zealand Pharma. The registered enrollment target is 221 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (73% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06926842, a Phase 2 study of Obesity and Type 2 Diabetes, is active but no longer recruiting, sponsored by Zealand Pharma.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 221 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to investigate efficacy and safety of three doses of petrelintide versus placebo in participants with overweight or obesity and type 2 diabetes.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Petrelintide
Study Locations (20)
Florida
- Innovative Research of West Florida - Clearwater
- East Coast Institute for Research, LLC - Jacksonville
- Solutions Through Advanced Research, Inc - Jacksonville
- M3 Wake Research - Lake City - Lake City
- West Orange Endocrinology P.A - Ocoee
- Palm Beach Research Center - West Palm Beach
California
- Velocity Clinical Research - Huntington Park
- Velocity Clinical Research, North Hollywood - North Hollywood
- Exalt Clinical Research - San Diego
- Diablo Clinical Research Inc. - Walnut Creek
Arizona
- AZ Endocrine Institute - Chandler
- Elite Clinical Studies, LLC - Phoenix
- M3 Wake Research, Tucson Neuroscience Research, LLC - Tucson
Georgia
- M3 Wake Research - Atlanta - Atlanta
- East Coast Institute for Research - Canton - Canton
- Privia Medical Group Georgia, LLC - Savannah
Alabama
- Cullman Clinical Trials - Family Medicine - Cullman
Arkansas
- Medical Investigation Inc - Little Rock
Connecticut
- Chase Medical Research, LLC - Waterbury
District of Columbia
- Emerson Clinical Research - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 221 participants |
| Start Date | 2025-04-22 |
| Est. Completion | 2026-08-13 |
| Phase | Phase 2 |
What the registry record for NCT06926842 still lists
NCT06926842 is an interventional study that assigns participants to a tested intervention. The registered 221 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (73% lower).
The record links to 3 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06926842 names 20 study sites across 8 states, led by Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT06926842 about?
NCT06926842 is a clinical study titled "Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)". The main purpose of this study is to investigate efficacy and safety of three doses of petrelintide versus placebo in participants with overweight or obesity and type 2 diabetes.
What is the current status of trial NCT06926842?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 221 participants. The study started on 2025-04-22. Estimated completion is 2026-08-13.
What conditions does trial NCT06926842 study?
This clinical trial studies the following conditions: Obesity, Type 2 Diabetes, Overweight.
What interventions are being tested in trial NCT06926842?
The interventions under investigation include: Placebo (OTHER), Petrelintide (DRUG).
Who is sponsoring clinical trial NCT06926842?
This trial is sponsored by Zealand Pharma, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06926842 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06926842's enrollment target sits among peer trials
221 294th of 1053 higher than 759 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03170440 · 221 participants · NA
Non-invasive Nerve Stimulation for PTSD and Sleep
- NCT04939610 · 222 participants · Phase 1
A Study of 177Lu-FAP-2286 in Advanced Solid Tumors
- NCT05424783 · 222 participants
MRI And GPS Informing Choices for Prostate Cancer Treatment (MAGIC)
- NCT05568264 · 222 participants · NA
Effects of a Physical Therapy Intervention on Motor Delay in Infants Admitted to a Neonatal Intensive Care Unit
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI